Truist reiterates agilon health stock Hold rating at $112 target
Truist Securities has reiterated a Hold rating on agilon health Inc (NYSE:AGL) with a price target of $112.00, noting the company's infrastructure for improving patient outcomes and reducing unnecessary utilization. Despite the Hold rating, InvestingPro analysis suggests the stock is undervalued with a Fair Value of $155.30, and the company is expected to turn profitable this year, with recent Q3 2026 results exceeding expectations and leading to raised full-year guidance.
Agilon Health rated HOLD with 14.6% downside risk amid uncertain earnings and contract risks.
Agilon Health has been rated HOLD with a 12-month price target of $98, indicating a 14.6% downside risk from its recent closing price of $114.81. The company's future earnings sustainability is questioned due to volatile risk-score revenue and low claims reserves, despite a recent margin upgrade. Additionally, upcoming contract renegotiations and potential CMS audits present significant risks for the company.
AGL: agilon health inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
agilon health Inc. (AGL) filed an SEC Form 8-K announcing a virtual investor event on November 17, 2026, at 2:00 PM ET. The company furnished an investor presentation highlighting positive quality results, including a 4.2-star average Stars rating and 98% patient care satisfaction, while also providing forward-looking guidance for Q4 and full year 2026. The presentation materials are furnished, not filed, and therefore not subject to Section 18 liabilities of the Exchange Act.
Is agilon health (AGL) Fully Priced After Its 7x Run?
agilon health (AGL) has experienced a significant 7x stock price increase over the past year, prompting questions about its current valuation relative to sales. Despite trading at a P/S multiple of 0.3x, which is below sector and peer averages, a fair ratio framework suggests the stock is about right rather than aggressively priced. Analyst narratives offer both bull and bear cases, with some seeing the company as fairly valued due to a shift to profitability-focused growth, while others consider it overvalued due to potential revenue growth caps from weaker Medicare Advantage membership trends.
StoneX raises agilon health stock price target to $145 on guidance
StoneX has increased its price target for agilon health Inc (NYSE:AGL) to $145 from $140, maintaining a Buy rating, following the company's strong quarterly results and raised fiscal 2026 AEBITDA guidance. The updated guidance, nearly double previous estimates, reflects favorable cost trends and successful medical cost control. Agilon health also reported impressive Q3 2026 results, exceeding revenue and adjusted earnings per share forecasts.
StoneX raises agilon health stock price target to $145 on guidance
StoneX has increased its price target for agilon health Inc (NYSE:AGL) to $145 from $140, maintaining a Buy rating. This adjustment follows the company's strong third-quarter 2026 results, which included surpassing earnings and revenue expectations, and a significantly raised fiscal 2026 AEBITDA guidance. The firm expects continued growth through favorable cost trends, improved payer contracting, and strategic expansion.
5 insightful analyst questions from agilon health’s Q3 2026 earnings call
Agilon health (AGL) reported strong Q3 2026 results, surpassing analyst estimates for revenue, adjusted EPS, and adjusted EBITDA, driven by operational efficiency and clinical program performance. The company also raised its full-year revenue and EBITDA guidance. The article highlights key analyst questions from the earnings call, covering new market growth timelines, preference for risk-sharing contracts, participation in payer bonus revenue, drivers of improved financial trends, and progress on data pipeline integration.
Agilon Health Swings to $34.9 Million Q3 Profit, Raises 2026 Outlook
Agilon Health reported a swing to a $34.9 million net income in the third quarter of 2026, a significant improvement from a $110.2 million loss in the prior year. The company's revenue increased by 6% to $1.519 billion, and it raised its full-year 2026 revenue and Adjusted EBITDA outlook despite a decline in platform membership. CEO Tim O’Rourke attributed these results to disciplined execution and operational progress.
agilon health (AGL) shares skyrocket, what you need to know
Shares of healthcare services company Agilon Health (AGL) surged 17.5% after reporting strong third-quarter 2026 earnings, swinging from a net loss to a net profit of $35 million and achieving significant revenue growth. The company also saw a recovery in adjusted EBITDA and a decline in its medical services expense ratio, indicating improved operating efficiency. Despite high volatility and a substantial year-to-date gain, the stock remains below its 52-week high.
Agilon Health Q3 Earnings Call Highlights
Agilon Health (AGL) raised its full-year 2026 outlook after exceeding third-quarter guidance, driven by higher risk-adjustment revenue and favorable medical cost development. The company reported $1.5 billion in Q3 revenue, up 6%, and adjusted EBITDA of $64 million, compared to a loss a year prior. Agilon anticipates continued growth in accountable care organization membership and favorable payer contracts for 2027.
Agilon Health (AGL) Q3 Earnings and Revenues Surpass Estimates
Agilon Health (AGL) reported strong Q3 2026 earnings, with an adjusted profit of $1.97 per share, significantly beating analyst estimates of a loss. The company also exceeded revenue expectations, posting $1.52 billion against a consensus of $1.44 billion. Despite a mixed outlook for earnings estimate revisions, Agilon's stock has seen substantial year-to-date growth, outperforming the S&P 500.
Agilon Health Q3 2026 Earnings Call Transcript
Agilon Health exceeded its third-quarter guidance and raised its full-year 2026 outlook, driven by strong financial performance, favorable medical expense development, and effective clinical pathways. The company is focused on expanding its value-based care model, particularly within the Medicare Shared Savings Program, anticipating 40-50% ACO membership growth in 2027. Key initiatives include enhancing data capabilities for earlier patient intervention, advancing evidence-based clinical pathways for conditions like heart failure and dementia, and maintaining disciplined growth and payer contracting to ensure sustainable performance.
Agilon Health Inc. (AGL) Tops Q3 EPS by 319c
Agilon Health Inc. (AGL) reported strong third-quarter results, significantly exceeding analyst expectations. The company posted an EPS of $1.97, which was $3.19 higher than the estimated ($1.22), and revenue of $1.51 billion, surpassing the consensus estimate of $1.46 billion.
agilon health Reports Third Quarter 2026 Results
agilon health (NYSE: AGL) reported strong third-quarter 2026 results, exceeding expectations with a 6% increase in revenue to $1.52 billion and a significant improvement from a net loss to a net income of $35 million. The company also raised its full-year 2026 guidance, attributing the positive performance to disciplined execution, improved burden of illness performance, and favorable payor contracting, despite a slight decrease in total members.
agilon health earnings on deck: Can profitability hold?
Agilon health Inc. is set to report its third-quarter results, with investors keenly watching to see if the company can maintain the profitability turnaround it achieved last quarter. Analysts predict a loss of $1.22 per share on $1.46 billion in revenue, a notable shift from its Q2 profit. Key concerns include the sustainability of profitability, platform membership trends, and any updates to full-year guidance, all of which will determine whether the company's margin-focused strategy can deliver consistent returns.
agilon health (AGL) reports earnings tomorrow: what to expect
Agilon Health (AGL) is set to report its earnings, with analysts expecting a 1.6% year-on-year revenue growth. The company previously exceeded revenue and EPS estimates and increased its customer base. Investors will be watching closely, especially given past revenue misses, while the healthcare providers & services segment has seen positive sentiment recently.
agilon health stock: Third-quarter results set for November 4
Agilon Health (AGL) is scheduled to release its third-quarter 2026 results after the market close on November 4, 2026, followed by a conference call at 4:30 p.m. ET. Investors will be looking for updates on physician partnerships, medical-cost management, and contract economics in the value-based senior care sector. The company partners with physician groups and health systems to transition senior patients to a value-based Total Care Model, operating across approximately 30 communities with 2,300 primary care physicians.
agilon health, inc. (AGL) Seasonal returns chart
The article displays the historical seasonality chart for agilon health, inc. (AGL), showing average monthly price returns from 2021 to 2026. It also provides current stock information, including the closing price and after-hours trading data.
agilon health, inc. (AGL) Seasonal Returns Chart
The article provides a seasonal returns chart for agilon health, inc. (AGL), displaying the average monthly price return between 2021 and 2026. It includes stock performance data, showing AGL's closing price and after-hours trading activity on October 30. The chart allows users to view seasonality over various timeframes such as 3Y, 5Y, 10Y, 20Y, and All.
agilon health, inc. Estimates – NYSE:AGL
This page on TradingView provides financial data and analyst estimates for agilon health, inc. (NYSE: AGL). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements, including income statement, balance sheet, and cash flow. The platform also allows visualization of trends over time for this health services company.
agilon health (AGL): Buy, Sell, or Hold Post Q2 Earnings?
Agilon health (AGL) has seen a significant stock price increase of 275% in the past six months, partly due to strong quarterly results. The company, which helps primary care physicians transition to value-based care for Medicare patients, boasts impressive five-year compounded annual revenue growth of 30.8% and an expanding free cash flow margin. However, a declining customer base, with a 3.1% year-on-year average decline over the last two years, raises concerns about potential competition or market saturation.
A Look at Agilon Health Inc (AGL) After 4.4% Gain -- GF Value $9
Agilon Health Inc (AGL) saw a 4.4% stock gain, pushing its year-to-date performance to 415.9%. Despite being unprofitable, the stock is considered slightly undervalued by GF Value, and its GF Score of 78/100 indicates above-average performance, driven by strong growth and valuation ranks. Gurus and insiders have shown confidence by increasing their positions, suggesting potential future value.
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
Shares of Moderna, Progyny, Azenta, Oscar Health, and agilon health all surged in the afternoon session as investors shifted towards defensive assets and anticipated potential changes in federal spending policies after midterm elections. This market movement is attributed to growing expectations that a Democratic gain in midterm elections could reverse or ease healthcare spending cuts implemented under President Trump's 2025 spending bill, benefiting the healthcare sector. Azenta, in particular, saw a 3.5% jump, though its shares remain volatile and are still trading below its 52-week high despite a year-to-date gain.
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
Shares of Moderna, Progyny, Azenta, Oscar Health, and agilon health surged due to a shift by investors into defensive assets and growing expectations that midterm election outcomes could reverse recent federal healthcare spending cuts. This potential political shift is seen as positive for the healthcare industry, protecting funding and demand. Azenta, despite recent volatility, saw a 3.5% jump amidst these market dynamics.
Agilon Health (AGL) Short Interest & Short Float | Updated Oct 2026 $AGL
Agilon Health (AGL) reported a short interest of 1.01 million shares as of September 30, 2026, representing 6.16% of its public float, a 3.99% decrease from the previous report. The short interest ratio stands at 3.8 days to cover, indicating that it would take nearly four days to cover all short positions based on average trading volume. This report provides detailed historical short interest data for AGL and compares it to other companies in the healthcare services sector.
Is It Too Late to Buy Agilon Health Inc (AGL) After 3.8% Rally? GF Value Says Undervalued
Agilon Health Inc (AGL) saw its shares rally by 3.8% to $85.49, yet GuruFocus's GF Value™ suggests it is still 5.8% undervalued at $90.76. Despite this, the company faces profitability and cash-flow challenges, making traditional valuation methods difficult. Insiders have shown confidence by purchasing $0.4 million in shares, with four gurus also increasing their stakes.
Bernstein Maintains Agilon Health(AGL.US) With Buy Rating, Maintains Target Price $125
Bernstein analyst Lance Wilkes has reaffirmed a "Buy" rating for Agilon Health (AGL.US) and maintained a target price of $125. According to TipRanks data, Wilkes has a 51.0% success rate and a 9.0% average return over the past year, indicating a positive track record for their recommendations. This information is provided for informational purposes only and is not an investment recommendation.
A 4:30 p.m. call will cover agilon health's third-quarter results on Nov. 4.
Agilon health (NYSE: AGL) announced it will release its third-quarter 2026 financial results after market close on November 4, 2026. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the call via phone or a simultaneous webcast on agilon's Investor Relations website.
agilon health Sets Date to Report Third Quarter 2026 Financial Results
agilon health (NYSE: AGL) announced it will release its third-quarter 2026 financial results after market close on Wednesday, November 4, 2026. The company will host a conference call at 4:30 p.m. ET to discuss these results, accessible via phone and webcast. agilon health partners with physicians to transform healthcare to a value-based Total Care Model, focusing on senior patients.
agilon health Inc (NYSE: AGL) Share Price, AGL Stock News, AGL Share Price & Updates
This article provides an overview of agilon health Inc (NYSE: AGL), a company offering healthcare services for seniors through primary care physicians, utilizing a technology-enabled platform. It details the company's stock price, key financial metrics, income statement, balance sheet, cash flow breakdown, and a peer comparison. The AI summary highlights long-term growth drivers like aging demographics and Medicare Advantage enrollment, alongside risks such as policy changes and execution challenges.
agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO
agilon health and The Jackson Clinic are expanding their partnership through agilon’s Senior Health Connect ACO to improve care for Traditional Medicare beneficiaries in Tennessee. The Jackson Clinic, a large independent physician organization, will leverage agilon's technology and expertise to enhance coordinated care, chronic disease management, and patient outcomes for an additional 9,000 beneficiaries. This builds on their existing collaboration, which already supports approximately 8,000 Medicare Advantage patients in a value-based care model.
About 9,000 more people on traditional Medicare may be reached as a Tennessee clinic joins a care program.
Agilon health (NYSE: AGL) and The Jackson Clinic are expanding their partnership, with The Jackson Clinic joining agilon's Senior Health Connect ACO. This collaboration aims to extend value-based care to approximately 9,000 additional Traditional Medicare beneficiaries in Tennessee, building on their existing work with 8,000 Medicare Advantage patients. The initiative focuses on improving quality, patient outcomes, and chronic disease management while reducing healthcare spending.
agilon health, inc. (AGL) options chain
This article provides the options chain data for agilon health, inc. (AGL), showing delayed quotes for calls and puts. As of the report, there are no active calls or puts listed in the money, indicating limited options trading activity or availability for the specified conditions. It includes summary, news, chart, statistics, historical data, profile, financials, analysis, and options information for AGL.
agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO
agilon health announced an expansion of its partnership with Springfield Clinic, bringing the clinic into one of agilon's Senior Health Connect ACOs. This collaboration aims to extend value-based care to an additional 21,000 Traditional Medicare beneficiaries in Illinois, building on their existing partnership for Medicare Advantage patients. The initiative focuses on improving quality outcomes, coordinating care, and reducing healthcare spending through agilon's proven ACO model.
Stocks making big moves yesterday: Dave & Buster's, Vishay Intertechnology, DocuSign, SentinelOne, and agilon health
This article highlights several stocks that experienced significant movement yesterday, including Dave & Buster's (PLAY) which fell due to a poor earnings report. In contrast, Vishay Intertechnology (VSH), DocuSign (DOCU), SentinelOne (S), and agilon health (AGL) all saw their stock prices rise following positive analyst coverage, industry recognition, or upgrades. The article provides a brief reason for each company's performance.
Bernstein upgrades Agilon Health stock rating on turnaround progress
Bernstein SocGen Group has upgraded Agilon Health (NYSE: AGL) to Outperform from Market Perform, raising its price target to $125.00 due to the company's significant turnaround progress. Agilon Health has seen a 516% stock surge over six months, driven by improved risk-taking discipline, medical cost management, and a focus on profitability over growth. The company reported adjusted EBITDA of $70 million in Q2 2026, a substantial improvement from a negative $83 million in 2025, and analysts anticipate continued profitability.
agilon health upgraded at Bernstein on turnaround progress
Bernstein has upgraded agilon health (AGL) to outperform from market-perform, citing positive results from the company's turnaround efforts. The firm also increased its price target for AGL to $125 from $86, representing a potential 35% upside based on the stock's closing price on September 14. This upgrade signals confidence in the company's recent strategic improvements.
Bernstein Upgrades Agilon Health to Outperform From Market Perform, Adjusts Pt to $125 From $86
Bernstein has upgraded Agilon Health (AGL) from a "Market Perform" rating to an "Outperform" rating, significantly increasing its price target to $125 from $86. This positive revision reflects a strong analyst confidence in the healthcare company's future performance. The article also mentions recent activities and other analyst adjustments for Agilon Health, including expansions and other rating changes.
agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO
agilon health and Family Practice Center (FPC) are expanding their partnership through agilon's Senior Health Connect ACO to improve care for Traditional Medicare beneficiaries in Pennsylvania. FPC, central Pennsylvania's largest independent primary care group, will leverage agilon's expertise in value-based care models, technology, and AI-enabled platforms to enhance chronic disease management, care coordination, and preventive care. This collaboration aims to deliver better health outcomes and reduce healthcare costs, building on agilon's track record of generating significant savings and achieving high-quality scores in previous ACO models.
agilon health is set for three September health conference events
agilon health (NYSE: AGL) announced its management team will participate in three healthcare conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Jefferies Healthcare Services and Technology Conference, and Deutsche Bank's 2026 Healthcare Summit. Investors can access webcasts or replays of applicable presentations through the company's investor relations website. The company is a trusted partner for physicians, empowering them to transition to a value-based Total Care Model for senior patients.
Agilon Health (NYSE:AGL) Trading Down 5.6% - Here's What Happened
Agilon Health (NYSE:AGL) experienced a 5.6% drop in its stock price, trading down to $87.35 with significantly reduced trading volume. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable. Analyst sentiment is mixed, with a consensus "Hold" rating and institutional investors showing varied activity in their holdings.
Rubicon Founders LLC Purchases Shares of 105,341 Agilon Health, Inc. $AGL
Rubicon Founders LLC acquired a new position in Agilon Health, Inc. (NYSE:AGL) during the second quarter, purchasing 105,341 shares valued at approximately $11.29 million. Other institutional investors also adjusted their holdings, while analysts provided mixed ratings for Agilon Health, with an average target price of $97.70. The company reported strong quarterly earnings, beating consensus estimates, but faces a negative return on equity and net margin.
agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference
agilon health, inc. (NYSE: AGL) has announced a revised presentation time for its management team at the 2026 Jefferies Healthcare Services and Technology Conference. The fireside chat is now scheduled for Monday, September 14, 2026, at 4:00 PM ET. Interested investors can access a live webcast and replays on the company's investor relations website.
Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
Agilon Health (AGL) has significantly outperformed its Medical sector peers and the overall Medical Services industry this year, returning 215% compared to the sector's -8.2% and the industry's -11%. This strong performance is supported by a Zacks Rank of #2 (Buy) and a 47.5% increase in its full-year earnings consensus estimate. Another strong performer mentioned is Amarin (AMRN), which is up 7.9% year-to-date and holds a Zacks Rank #1 (Strong Buy).
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)
This article provides analyst ratings and price targets for three healthcare companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING), and Agilon Health (AGL). Eloxx Pharmaceuticals received a Strong Buy consensus with a $40.33 average price target. Cingulate Inc also has a Strong Buy consensus with a $20.25 price target, while Agilon Health has a Hold consensus with a $116.75 average price target.
Truist reiterates Hold on agilon health stock, $112 target
Truist Securities has reiterated a Hold rating on agilon health Inc (NYSE:AGL) with a price target of $112.00, despite the stock currently trading at $95.92. The firm's optimism follows a non-deal roadshow where agilon health management expressed confidence in the company's strengthened foundation and shift towards value creation. This comes after the company reported strong Q2 2026 earnings and revenue, surpassing Wall Street expectations and leading to a raised full-year outlook.
Truist reiterates Hold on agilon health stock, $112 target
Truist Securities reiterated a Hold rating on agilon health Inc (NYSE:AGL) with a $112.00 price target, despite the stock currently trading at $95.92. The firm's optimism stems from recent meetings where agilon health management expressed confidence in the company's strong foundation, improved data visibility, and progress in clinical programs and payer relationships. This positive outlook is further supported by the company's extraordinary 881% return over the past six months and a recent beat on second-quarter earnings and revenue expectations.
Truist on agilon health Inc (AGL): 'From Stabilization to Value Creation'
Truist Securities analyst Jailendra Singh reiterated a Hold rating and an $112.00 price target for agilon health Inc (NYSE: AGL). The article provides this analyst's commentary on the company, titled 'From Stabilization to Value Creation'. Access to the full article requires a StreetInsider.com Premium subscription.
Agilon Health (AGL) Q1 Earnings and Revenues Top Estimates
Agilon Health (AGL) reported first-quarter earnings of $1.8 per share, significantly surpassing the Zacks Consensus Estimate of $1.13, and revenues of $1.42 billion, also beating estimates. Despite a decrease in year-over-year revenues, the company has topped consensus revenue estimates in three of the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Q2 Earnings Highlights: agilon health (NYSE:AGL) Vs The Rest Of The Outpatient & Specialty Care Stocks
This article analyzes the Q2 earnings reports of several outpatient and specialty care stocks, comparing their performance, revenue growth, and market reactions. While agilon health exceeded analyst expectations for revenue and EBITDA guidance, its stock declined due to higher investor expectations. LifeStance Health Group, U.S. Physical Therapy, Surgery Partners, and Encompass Health also reported their Q2 results, with LifeStance Health Group showing the strongest performance among the group.